MONTGOMERY, Texas--(BUSINESS WIRE)--March 6, 2006--Endovasc, Inc. - (OTCBB: EVSC) a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine, announced today that the Company has submitted to the U.S. Food and Drug Administration (FDA) its protocol for a Phase IIIa clinical trial of Liprostin(TM) for the treatment of intermittent claudication, a symptom of peripheral arterial disease.
